Clinical trials: Kaposi Sarcoma
Sarcoma, Kaposi, HIV Infections
Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders
To evaluate topical A-007 in patients with advanced malignancies including Kaposi's sarcoma and lymphoproliferative disorders.
- Conditions
- Sarcoma, Kaposi, HIV Infections, Lymphoproliferative Disorders
- Trial name
- NCT00002153
- Testing
- A-007
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- DEKK-TEC, Inc.
Kaposi Sarcoma, HIV Infections
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
To determine the safety of escalating IV doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS and to compare results obtained from subcutaneous and IV administrations of Tc 99m tilmanocept…
- Trial name
- NCT03157167
- Testing
- Tc99m-tilmanocept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Navidea Biopharmaceuticals
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03886181
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Sarcoma, Kaposi, HIV Infections
A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy ABV: Adriamycin…
- Trial name
- NCT00002318
- Testing
- Doxorubicin hydrochloride (liposomal), Bleomycin sulfate, Vincristine sulfate
- Where
- 28 sites in United States
- Volunteers
- 225 people
- Sponsor
- Sequus Pharmaceuticals
Sarcoma, Kaposi, HIV Infections
Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma
To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of moderate to severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy BV (bleomycin/vincristine).
- Trial name
- NCT00002105
- Testing
- Doxorubicin hydrochloride (liposomal), Bleomycin sulfate, Vincristine sulfate
- Where
- 4 sites in United States
- Volunteers
- 220 people
- Sponsor
- Sequus Pharmaceuticals
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Ovarian Cancer, AIDS-related Kaposi Sarcoma
Doxil/Caelyx BE Study
The aim of this study is to demonstrate the bioequivalence of DOXIL/CAELYX, 40 mg/m2 (IV infusion over 90 minutes) between two manufacturing facilities.
- Conditions
- Ovarian Cancer, AIDS-related Kaposi Sarcoma, Multiple Myeloma, Metastatic Breast Cancer
- Trial name
- NCT05567601
- Testing
- DOXIL/CAELYX
- Where
- 14 sites in India
- Volunteers
- 36 people
- Sponsor
- Baxter Healthcare Corporation
Sarcoma, Kaposi, HIV Infections
A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma
To evaluate the safety and effectiveness of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the long-term treatment of AIDS-related Kaposi's sarcoma (KS) in patients who previously had good responses to DOX-SL in…
- Trial name
- NCT00002319
- Testing
- Doxorubicin hydrochloride (liposomal)
- Where
- 33 sites in United States
- Sponsor
- Sequus Pharmaceuticals
Sarcoma
SU5416 in Treating Patients With AIDS-Related Kaposi's Sarcoma
RATIONALE: SU5416 may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor. PURPOSE: Phase I trial to study the effectiveness of SU5416 in treating patients who have AIDS-related Kaposi's sarcoma.
- Trial name
- NCT00003720
- Testing
- semaxanib
- Where
- 4 sites in United States
- Sponsor
- Pfizer
Sarcoma, Kaposi, HIV Infections
Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma.
To provide Stealth liposomal doxorubicin hydrochloride ( DOX-SL ) as a therapy for Kaposi's sarcoma patients who have no remaining treatment options other than DOX-SL or patients who have been participating in another DOX-SL…
- Trial name
- NCT00002147
- Testing
- Doxorubicin hydrochloride (liposomal)
- Where
- United States
- Sponsor
- Sequus Pharmaceuticals
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Hodgkin Disease, Lymphoma, Large-Cell
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies
The purpose of this study is to evaluate a multi-dose regimen of SGN-30, a novel chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies.
- Conditions
- Hodgkin Disease, Lymphoma, Large-Cell, Sarcoma, Kaposi, Lymphoma, T-Cell, Cutaneous
- Trial name
- NCT00051597
- Testing
- SGN-30 (monoclonal antibody)
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- Seagen Inc.
Kaposi Sarcoma
A Study of sEphB4-HSA in Kaposi Sarcoma
sEphB-HSA may prevent tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor.
- Trial name
- NCT03993106
- Testing
- sEphB4-HSA
- Where
- 3 sites in United States
- Volunteers
- 65 people
- Sponsor
- Vasgene Therapeutics, Inc
Sarcoma, Kaposi, HIV Infections
A Study of Ro 24-7429 in Patients With HIV-Related Kaposi's Sarcoma
To study the effects of Ro 24-7429 on tumor growth in patients with HIV-related Kaposi's sarcoma. To study the safety and tolerance, effects on HIV replication, and immunologic effects of Ro 24-7429 in this patient population.
- Trial name
- NCT00002314
- Testing
- Ro 24-7429
- Where
- 2 sites in United States
- Sponsor
- Hoffmann-La Roche
Sarcoma, Kaposi, HIV Infections
A Study of Targretin Capsules in Patients With AIDS-Related Kaposi's Sarcoma
The purpose of this study is to see if it is safe and effective to give Targretin capsules to patients with AIDS-related Kaposi's sarcoma (KS).
- Trial name
- NCT00002212
- Testing
- Bexarotene
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Ligand Pharmaceuticals
Sarcoma, Kaposi, HIV Infections
A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
- Trial name
- NCT00002137
- Testing
- Tecogalan sodium
- Where
- United States
- Sponsor
- Daiichi Pharmaceuticals
Sarcoma, Kaposi, HIV Infections
Safety and Effectiveness of Giving SU5416 to HIV-Infected Patients With AIDS-Related Kaposi's Sarcoma
The purpose of this study is to see if it is safe and effective to give SU5416 to HIV-infected patients with AIDS-related Kaposi's sarcoma (KS). SU5416 may prevent the growth of KS tumors.
- Trial name
- NCT00002226
- Testing
- SU5416
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- SUGEN
Sarcoma, Kaposi, HIV Infections
Paclitaxel in Advanced Refractory Kaposi's Sarcoma (AIDS-KS): A Phase II Trial of Paclitaxel From Baker Norton Pharmaceuticals
To determine response rate, median time to tumor progression, qualitative and quantitative toxicity and reversibility of toxicity in patients with advanced refractory AIDS-associated Kaposi's sarcoma (KS) administered a 3-hour…
- Trial name
- NCT00002189
- Testing
- Paclitaxel
- Where
- United States
- Sponsor
- Baker Norton Pharmaceuticals
Kaposi's Sarcoma, HIV Positive
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.
- Conditions
- Kaposi's Sarcoma, HIV Positive, AIDS
- Trial name
- NCT02029430
- Testing
- 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- ImmunityBio, Inc.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma
L19IL2/L19TNF in Skin Cancer Patients
Phase II, open label, multicentric, proof-of-principle basket trial in patients with malignant tumors of the skin amenable to intratumoral injection, and in a curative or neoadjuvant or palliative intention.
- Conditions
- BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin
- Trial name
- IntriNSiC (NCT05329792)
- Testing
- L19IL2/L19TNF
- Where
- 14 sites in France, Italy and 1 more
- Volunteers
- 70 people
- Sponsor
- Philogen S.p.A.